AmirAli Talasaz

AmirAli Talasaz, PhD is the co-CEO of Guardant Health, a leading precision oncology company he co-founded in 2012 with Dr. Helmy Eltoukhy. Under AmirAli’s leadership, Guardant is transforming cancer care through advanced blood tests that discover cancer sooner and guide more precise treatment. Talasaz has been recognized by TIME100 Health as one of the most influential people in global health and by Fortune (40 Under 40). He was named to Time Magazine’s inaugural list of the 50 Most Influential People in Health Care and has received the PMWC Luminary Award for his work advancing the science of cancer care and screening. Prior to co-founding Guardant Health, Talasaz founded Auriphex Biosciences, a transformative biotech focused on purification and genetic analysis of circulating tumor cells for cancer management, which was acquired by Illumina in 2009. At Illumina, he served as senior director of Diagnostics Research, focused on emerging clinical applications of next-generation genomic analysis. Talasaz holds a BS in electrical engineering from Sharif University of Technology and an MS in management science and PhD in electrical engineering from Stanford University, where he led the Technology Development Group at the Stanford Genome Technology Center.